Protective role of neuronal and lymphoid cannabinoid CB2 receptors in neuropathic pain

  1. David Cabañero
  2. Angela Ramírez-López
  3. Eva Drews
  4. Anne Schmöle
  5. David M Otte
  6. Agnieszka Wawrzczak-Bargiela
  7. Hector Huerga Encabo
  8. Sami Kummer
  9. Antonio Ferrer-Montiel
  10. Ryszard Przewlocki
  11. Andreas Zimmer
  12. Rafael Maldonado  Is a corresponding author
  1. Universitat Pompeu Fabra, Spain
  2. University of Bonn, Germany
  3. Polish Academy of Sciences, Poland
  4. Universidad Miguel Hernández, Spain

Abstract

Cannabinoid CB2 receptor (CB2) agonists are potential analgesics void of psychotropic effects. Peripheral immune cells, neurons and glia express CB2, however the involvement of CB2 from these cells in neuropathic pain remains unresolved. We explored spontaneous neuropathic pain through on-demand self-administration of the selective CB2 agonist JWH133 in wild-type and knockout mice lacking CB2 in neurons, monocytes or constitutively. Operant self-administration reflected drug-taking to alleviate spontaneous pain, nociceptive and affective manifestations. While constitutive deletion of CB2 disrupted JWH133-taking behavior, this behavior was not modified in monocyte-specific CB2 knockouts and was increased in mice defective in neuronal CB2 knockouts suggestive of increased spontaneous pain. Interestingly, CB2-positive lymphocytes infiltrated the injured nerve and possible CB2transfer from immune cells to neurons was found. Lymphocyte CB2depletion also exacerbated JWH133 self-administration and inhibited antinociception. This work identifies a simultaneous activity of neuronal and lymphoid CB2that protects against spontaneous and evoked neuropathic pain.

Data availability

All experimental data and statistical analyses of this study are included in the manuscript and its supplementary files. Raw data and results of statistical analyses are provided in the Source Data File and its containing data sheets.

Article and author information

Author details

  1. David Cabañero

    Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1133-0908
  2. Angela Ramírez-López

    Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  3. Eva Drews

    Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany
    Competing interests
    The authors declare that no competing interests exist.
  4. Anne Schmöle

    Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. David M Otte

    Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Agnieszka Wawrzczak-Bargiela

    Department of Molecular Neuropharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
    Competing interests
    The authors declare that no competing interests exist.
  7. Hector Huerga Encabo

    Immunology Unit, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  8. Sami Kummer

    Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  9. Antonio Ferrer-Montiel

    Institute of Research, Development and Innovation in Healthcare Biotechnology of Elche (IDiBE), Universidad Miguel Hernández, Elche, Alicante, Spain
    Competing interests
    The authors declare that no competing interests exist.
  10. Ryszard Przewlocki

    Department of Molecular Neuropharmacology, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
    Competing interests
    The authors declare that no competing interests exist.
  11. Andreas Zimmer

    Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany
    Competing interests
    The authors declare that no competing interests exist.
  12. Rafael Maldonado

    Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain
    For correspondence
    rafael.maldonado@upf.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4359-8773

Funding

European Commission (FP7-602891-2)

  • Rafael Maldonado

Instituto de Salud Carlos III (RD12/0028/0023/FEDER)

  • Rafael Maldonado

Ministerio de Economía y Competitividad (SAF2014-59648-P)

  • Rafael Maldonado

Generalitat de Catalunya (2014-SGR-1547)

  • Rafael Maldonado

Generalitat de Catalunya (2018 FI_B 00207)

  • Angela Ramírez-López

Polish Ministry of Science and Education (3070/7.PR/2014/2)

  • Ryszard Przewlocki

Universidad Miguel Hernandez (UMH-PAR2019)

  • Antonio Ferrer-Montiel

Spanish Ministry of Science, Innovation and Universities (RTI2018-097189-B-C21)

  • Antonio Ferrer-Montiel

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Allan Basbaum, University of California San Francisco, United States

Ethics

Animal experimentation: Animal handling and experiments were in accordance with protocols approved by the respective Animal Care and Use Committees of the PRBB, Departament de Territori i Habitatge of Generalitat de Catalunya and the Institute of Molecular Psychiatry and were performed in accordance with the European Communities Council Directive (2010/63/EU).

Version history

  1. Received: January 29, 2020
  2. Accepted: July 19, 2020
  3. Accepted Manuscript published: July 20, 2020 (version 1)
  4. Version of Record published: July 27, 2020 (version 2)
  5. Version of Record updated: August 3, 2020 (version 3)

Copyright

© 2020, Cabañero et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,521
    Page views
  • 247
    Downloads
  • 31
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, Scopus, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. David Cabañero
  2. Angela Ramírez-López
  3. Eva Drews
  4. Anne Schmöle
  5. David M Otte
  6. Agnieszka Wawrzczak-Bargiela
  7. Hector Huerga Encabo
  8. Sami Kummer
  9. Antonio Ferrer-Montiel
  10. Ryszard Przewlocki
  11. Andreas Zimmer
  12. Rafael Maldonado
(2020)
Protective role of neuronal and lymphoid cannabinoid CB2 receptors in neuropathic pain
eLife 9:e55582.
https://doi.org/10.7554/eLife.55582

Share this article

https://doi.org/10.7554/eLife.55582

Further reading

    1. Neuroscience
    Kiwamu Kudo, Kamalini G Ranasinghe ... Srikantan S Nagarajan
    Research Article

    Alzheimer’s disease (AD) is characterized by the accumulation of amyloid-β and misfolded tau proteins causing synaptic dysfunction, and progressive neurodegeneration and cognitive decline. Altered neural oscillations have been consistently demonstrated in AD. However, the trajectories of abnormal neural oscillations in AD progression and their relationship to neurodegeneration and cognitive decline are unknown. Here, we deployed robust event-based sequencing models (EBMs) to investigate the trajectories of long-range and local neural synchrony across AD stages, estimated from resting-state magnetoencephalography. The increases in neural synchrony in the delta-theta band and the decreases in the alpha and beta bands showed progressive changes throughout the stages of the EBM. Decreases in alpha and beta band synchrony preceded both neurodegeneration and cognitive decline, indicating that frequency-specific neuronal synchrony abnormalities are early manifestations of AD pathophysiology. The long-range synchrony effects were greater than the local synchrony, indicating a greater sensitivity of connectivity metrics involving multiple regions of the brain. These results demonstrate the evolution of functional neuronal deficits along the sequence of AD progression.

    1. Medicine
    2. Neuroscience
    Luisa Fassi, Shachar Hochman ... Roi Cohen Kadosh
    Research Article

    In recent years, there has been debate about the effectiveness of treatments from different fields, such as neurostimulation, neurofeedback, brain training, and pharmacotherapy. This debate has been fuelled by contradictory and nuanced experimental findings. Notably, the effectiveness of a given treatment is commonly evaluated by comparing the effect of the active treatment versus the placebo on human health and/or behaviour. However, this approach neglects the individual’s subjective experience of the type of treatment she or he received in establishing treatment efficacy. Here, we show that individual differences in subjective treatment - the thought of receiving the active or placebo condition during an experiment - can explain variability in outcomes better than the actual treatment. We analysed four independent datasets (N = 387 participants), including clinical patients and healthy adults from different age groups who were exposed to different neurostimulation treatments (transcranial magnetic stimulation: Studies 1 and 2; transcranial direct current stimulation: Studies 3 and 4). Our findings show that the inclusion of subjective treatment can provide a better model fit either alone or in interaction with objective treatment (defined as the condition to which participants are assigned in the experiment). These results demonstrate the significant contribution of subjective experience in explaining the variability of clinical, cognitive, and behavioural outcomes. We advocate for existing and future studies in clinical and non-clinical research to start accounting for participants’ subjective beliefs and their interplay with objective treatment when assessing the efficacy of treatments. This approach will be crucial in providing a more accurate estimation of the treatment effect and its source, allowing the development of effective and reproducible interventions.